Rootology Competitors and Similar CompaniesClear all

Rootology's competitors and similar companies include Akums Drugs and Pharmaceuticals, Bausch Health Americas, Hypera Pharma and Innovent Biologics.

	Rootology Rootology is a company developing natural products that provide nasal and sinus support.	Akums Drugs and Pharmaceuticals Akums Drugs and Pharmaceuticals is a contract development and manufacturing organization (CDMO).	Bausch Health Americas Bausch Health Americas (BHA) is a pharmaceutical preparation manufacturing company.	Hypera Pharma Hypera Pharma is a pharmaceutical company that provides medicines and food supplements.	Innovent Biologics Innovent Biologics is a biopharmaceutical company that develops and manufactures drugs.
Founding Date	Founding Date N/A	Founding Date 2004	Founding Date 1994	Founding Date 2001	Founding Date 2011
Type	Type Private	Type Private	Type Subsidiary	Type Public	Type Public
Tags	Tags Manufacturing & Industrial drug development pharma	Tags Healthcare drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma
Locations	Locations Cincinnati, US HQ	Locations Delhi, IN HQ Delhi, IN	Locations Bridgewater, US HQ Laval, CA Steinbach, CA Envigado, CO La Estrella, CO Medellín, CO Ciudad De México, MX see more	Locations São Paulo, BR HQ	Locations Suzhou, CN HQ
Employees	Employees N/A	Employees 4,4829% increase	Employees 4,044	Employees 10,481	Employees 5,659
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) R$7.7b (FY, 2025)	Revenue (est.) ¥13b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods R$2.8b (FY, 2025)	Cost of goods ¥1.1b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit R$4.9b (FY, 2025)	Gross profit ¥12b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income R$1.2b (FY, 2025)	Net income ¥813.6m (FY, 2025)